Metraipolis › archive › dc_281f870df145

Ceftazidime-avibactam for multidrug-resistant gram-negative infections: outcomes and timing of initiation across 22 U.S. medical centers — Europe PMC PMID:42138697

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42138697
DOI
10.1128/aac.00268-26
License (as archived)
solo-consultazione
Archived
2026-11-02T07:22:50.329Z
SHA-256 of the archived text
1897091c7d4f54913334b89dc9d73791a47edb62e3b608e4c909a1ad4723407a
Stable URL of this page
https://metraipolis.com/documento/dc_281f870df145

How to cite

Ceftazidime-avibactam for multidrug-resistant gram-negative infections: outcomes and timing of initiation across 22 U.S. medical centers — Europe PMC PMID:42138697 — Europe PMC (en), https://europepmc.org/article/MED/42138697 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_281f870df145 (Metraipolis archive dc_281f870df145, sha256 1897091c7d4f54913334b89dc9d73791a47edb62e3b608e4c909a1ad4723407a)
BibTeX
@misc{dc281f870df145,
  title = {Ceftazidime-avibactam for multidrug-resistant gram-negative infections: outcomes and timing of initiation across 22 U.S. medical centers — Europe PMC PMID:42138697},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42138697},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_281f870df145; sha256 1897091c7d4f54913334b89dc9d73791a47edb62e3b608e4c909a1ad4723407a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42138697. Agents can read the archived copy with the MCP tool read_document.